Skip to content

Study · Animal study (in vivo) · rat · 2003

6 results

Facilitative role of endogenous oxytocin in noradrenaline release in the rat supraoptic nucleus.

Onaka T, Ikeda K, Yamashita T, Honda K

The European journal of neuroscience1 Dec 2003Cited by 27 (Europe PMC)

PMID14656297 (opens in a new tab)DOI10.1046/j.1460-9568.2003.03037.x (opens in a new tab)PepBankPUB-14656297
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In rats, local application of oxytocin augmented high-K+-induced noradrenaline release in the hypothalamic supraoptic nucleus.

    In plain wordsIn rats, oxytocin applied to one brain area increased the release of noradrenaline.

    Peptide
    Oxytocin
    Outcome
    IncreaseHigh-K+-induced noradrenaline release in the supraoptic nucleus (in vivo)
    Study

    ratn: not reported in source

    rat hypothalamic supraoptic nucleus
    Outcome group
    Neurotransmitters and neurotrophic factors · Nervous system and cognition
    Studied dose
    Dose not stated · local applicationAs given in this study (rat).

    Source sentences

    Summary
    In vivo microdialysis experiments showed that local application of oxytocin augmented high-K+-induced noradrenaline release in the hypothalamic supraoptic nucleus.
  2. 02LabEx vivo tissueMechanism

    In hypothalamic synaptosomes, oxytocin potentiated high-K+-induced noradrenaline release.

    In plain wordsIn lab tests on rat brain tissue preparations, oxytocin increased the release of noradrenaline.

    Peptide
    Oxytocin
    Outcome
    IncreaseHigh-K+-induced noradrenaline release in synaptosomes (in vitro)
    Study

    ratn: not reported in source

    hypothalamic synaptosomal preparation
    Outcome group
    Neurotransmitters and neurotrophic factors · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Oxytocin application to the hypothalamic synaptosomal preparation in vitro also potentiated high-K+-induced noradrenaline release.
  3. 03LabEx vivo tissueMechanism

    The effect of oxytocin on noradrenaline release was dose-dependent.

    In plain wordsIn lab tests on rat brain tissue, the effect of oxytocin on noradrenaline release became larger with higher doses.

    Peptide
    Oxytocin
    Outcome
    IncreaseDose dependence of oxytocin effect on noradrenaline release
    Study

    ratn: not reported in source

    hypothalamic synaptosomal preparation
    Outcome group
    Neurotransmitters and neurotrophic factors · Nervous system and cognition
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The effect of oxytocin was dose-dependent

Studies that did not test the peptide alone3

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

  1. 04AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Mechanism

    In rats, local application of an oxytocin receptor antagonist impaired noradrenaline release in the supraoptic nucleus in response to high-K+ solution or noxious stimuli.

    In plain wordsIn rats, blocking oxytocin receptors in one brain area reduced noradrenaline release after a trigger.

    Peptide
    Oxytocin
    Outcome
    DecreaseNoradrenaline release in the supraoptic nucleus after local oxytocin receptor antagonist
    Study

    ratn: not reported in source

    rat hypothalamic supraoptic nucleus
    Outcome group
    Neurotransmitters and neurotrophic factors · Nervous system and cognition

    Source sentences

    Summary
    Local application of an oxytocin receptor antagonist impaired noradrenaline release in the supraoptic nucleus in response to high-K+ solution or noxious stimuli.

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  2. 05AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Mechanism

    In rats, an i.c.v. injection of an oxytocin receptor antagonist impaired oxytocin release from the pituitary after noxious stimuli.

    In plain wordsIn rats, blocking oxytocin receptors in the brain reduced oxytocin release from the pituitary after a painful trigger.

    Peptide
    Oxytocin
    Outcome
    DecreasePituitary oxytocin release after noxious stimuli with i.c.v. oxytocin receptor antagonist
    Study

    ratn: not reported in source

    rats, i.c.v. injection with pituitary oxytocin release
    Outcome group
    Endogenous peptide levels · Endocrine and hormones

    Source sentences

    Summary
    An i.c.v. injection of an oxytocin receptor antagonist also impaired oxytocin release from the pituitary after noxious stimuli.

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

  3. 06LabNot a test of Oxytocin aloneEx vivo tissueMechanism

    An oxytocin receptor antagonist blocked the oxytocin-induced increase in noradrenaline release.

    In plain wordsIn lab tests on rat brain tissue, a drug that blocks oxytocin receptors stopped the effect of oxytocin on noradrenaline release.

    Peptide
    Oxytocin
    Outcome
    DecreaseOxytocin effect on noradrenaline release after oxytocin receptor antagonist
    Study

    ratn: not reported in source

    hypothalamic synaptosomal preparation
    Outcome group
    Neurotransmitters and neurotrophic factors · Nervous system and cognition

    Source sentences

    Summary
    and was blocked by an oxytocin receptor antagonist.

    In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 20:03 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.